Why Endo International Stock Rose 5.5% on June 12
On June 11, after the markets closed, Endo International (ENDP) announced that its subsidiaries Endo Pharmaceuticals and Auxilium Pharmaceuticals have entered into a master settlement agreement. This agreement is intended to resolve all known TRT (testosterone replacement therapy) product liability claims the company faces. The company said that the agreement isn’t expected to increase Endo’s product liability reserve, as the company has already recorded an accrual for the settlement in Q4 2017.